Individual high-net-worth investors providing early-stage capital to psychedelic startups and research initiatives.
Explore investor stakeholders by type, funding stage, and sector focus across the psychedelic ecosystem.
Investor Finder
Bicycle Day Ventures is a psychedelic-focused angel syndicate associated with Chris Kantrowitz. AngelList materials describe a syndicate thesis around psychedelic medicine and related industries, with visible portfolio exposure to companies including Beckley Psytech and Quantified Citizen. The syndicate remains a useful early-stage investor record because it is explicitly focused on psychedelic medicine, but its public identity fields are lighter than those of institutional funds. Public copy should stay precise about the syndicate structure and avoid overstating firm scale or office details.
Investor Category
Angel Investors
HQ
HQ: United States
Portfolio Signals
Series B · $80 million · Aug 16, 2021
Seed VC · undisclosed · Mar 17, 2022
Gaingels is a venture investment syndicate and network that co-invests with venture capital leads across a wide range of sectors and stages, from pre-seed to pre-IPO. Its public materials describe it as an LGBTQIA+/allies investor network focused on diversity, inclusion, and access in venture. The organization’s mailing address is in New York, New York, United States. Gaingels says it invests globally and supports venture-backed companies in any sector, with a notable emphasis on healthcare and biotech alongside other high-growth categories. In the psychedelic ecosystem, that makes it relevant as a potential co-investor for drug-development companies that fit its broader mental health and biotech orientation, even though its public portfolio page does not single out psychedelics as a dedicated focus.
Investor Category
Angel Investors
HQ
HQ: United States
Portfolio Signals
Public portfolio context is limited.
Kevin O'Leary is a Canadian entrepreneur and investor best known for his television role on Shark Tank and for building an investor brand around startups and private-market deals. His official site presents him as actively looking for new business proposals, and third-party profiles place him in Toronto, Ontario, Canada, while his public investor activity is global. In the psychedelic ecosystem, O'Leary is notable as an early investor and public advocate for MindMed, a psychedelic-focused drug-development company. Public interviews describe his interest as centered on regulated pharmaceutical development and binary, long-duration biotech-style outcomes rather than recreational use.
Investor Category
Angel Investors
HQ
HQ: Canada
Portfolio Signals
Seed · undisclosed · Jan 1, 2020
Matt Mullenweg is the co-founder and CEO of Automattic, the company behind WordPress.com, WooCommerce, Jetpack, and Tumblr, and he also describes Audrey Capital as an angel investment and research company. Public sources characterize him as an angel investor with a strong preference for open-source-oriented companies and early-stage startups. His relevance to the psychedelic ecosystem is indirect rather than thematic: available public materials do not show a specific psychedelic investment thesis or public psychedelic portfolio. He is still a useful investor to track in adjacent infrastructure and software circles because his investment activity is centered on early-stage, open-source-friendly businesses, not life sciences or psychedelic drug development.
Investor Category
Angel Investors
HQ
HQ: United States
Portfolio Signals
Public portfolio context is limited.
Mike Novogratz is an American investor and the founder and CEO of Galaxy, where he leads a global digital-assets and blockchain-focused investment platform. Public company filings list his principal business address in New York City, and Galaxy’s headquarters is also reported as New York City. He matters to the psychedelic ecosystem mainly as a public backer of psychedelic biopharma through atai Life Sciences, where investor lists and commentary name him among notable investors. Public references also link Novogratz to the broader psychedelic investment network alongside other prominent financiers involved in drug-development and mental-health innovation.
Investor Category
Angel Investors
HQ
HQ: United States
Portfolio Signals
private placement · undisclosed · Aug 1, 2019
Mission Club is an angel investor community and education platform. Public materials describe it as supporting the psychedelic ecosystem and related startups, with a focus on early-stage investing. The organization appears to be based in Toronto, Canada, based on a public event listing and a Canadian corporate registration record for a Mission Club entity. It has public ties to psychedelic community-building and investor programming rather than a large institutional fund structure.
Investor Category
Angel Investors
HQ
HQ: Canada
Portfolio Signals
Public portfolio context is limited.
Peter Thiel is a partner at Founders Fund, a Silicon Valley venture capital firm, and is publicly associated with investing through that platform. Public company materials also identify him as a named investor in atai Life Sciences financing rounds. In the psychedelic ecosystem, Thiel is relevant primarily through atai Life Sciences, a clinical-stage biotech company developing psychedelic and non-psychedelic compounds for mental health indications. atai’s financing announcements describe him as a co-lead investor in the company’s Series C round and as one of the investors in a later convertible note financing.
Investor Category
Angel Investors
HQ
HQ: United States
Portfolio Signals
Series C financing (co-led) · $125m financing round · Nov 23, 2020
Tim Ferriss is a U.S.-based angel investor, author, and podcast host who has been angel investing in tech and consumer packaged goods startups since 2008. His own site describes him as an early-stage technology investor/advisor and notes that most of his portfolio investments have been seed or Series A, with some later-stage positions. He matters in the psychedelic ecosystem because he has publicly backed psychedelic research and funding efforts, including major support for MDMA-assisted therapy and Johns Hopkins’ psychedelic research center. His public writing also says he shifted most of his focus away from startup investing and toward psychedelic science in 2015.
Investor Category
Angel Investors
HQ
HQ: United States
Portfolio Signals
philanthropic funding · part of $17 million in funding · Jan 1, 2019
philanthropic challenge grant · $10 million challenge · Jun 12, 2020